MetaCap

Enlivex (ENLV) vs Revelation Biosciences (REVB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enlivex is the larger company by market cap ($2.0 million vs $2.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENLV+242.69%REVB+322.65%
+823%+367%-88%
Oct 7, 20261 yearNov 20, 2026
ENLV+313.39%REVB+360.59%
+633%+282%-68%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENLV versus REVB key metrics
MetricENLVREVB
Share price$1.05$3.50
Market cap$2.01M$1.99M
1-day change-11.76%-5.15%
P/E ratio (TTM)0.00—
EPS (TTM)$7,904.00$-99.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.24B$-8.91M
52-week high$434.40$40.60
52-week low$1.00$3.08
Distance from 52-week high-99.76%-91.38%
Analyst consensusnonenone
Avg. price target upside+7519.05%+407.14%
Average volume73.14K12.49K
Shares outstanding1.91M569.06K
Employees348
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enlivex

ENLV stock →

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About Revelation Biosciences

REVB stock →

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

ENLV vs REVB FAQ

Which is bigger, Enlivex or Revelation Biosciences?

Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.99M for Revelation Biosciences (REVB).

Are Enlivex and Revelation Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons